The Significance of Tumor Budding and Immunohistochemical Axl Expression in Gallbladder Adenocarcinomas

Background: Tumor budding is a histopathological finding that is accepted as an indicator of epithelial-mesenchymal transformation in many solid tumors. Axl is a Receptor Tyrosine Kinase (RTK) family member and contributes to epithelial-mesenchymal transformation. It has been reported that its overexpression in various solid cancer cells is associated with a poor prognosis. It is claimed that Axl RTK may be the targeted molecule in treating some cancers due to its location in the cell membrane. Aims: To investigate the relationship between immunohistochemical (IHC) Axl expression with tumor budding on the histopathological level and their prognostic significance in patients with gallbladder carcinoma. Thus, it is aimed to contribute to the emergence of a molecular option for targeted, personalized therapy in these patients. Study Design: A retrospective cross-sectional study Methods: Thirty-eight gallbladder cancer patients who underwent surgery between 2000 and 2017 were included in the study. The expressions of Axl RTK in tumor tissues were evaluated by the IHC method. Demographic data (age, sex) of patients, histopathological features (size, growth pattern), tumor differentiation, pathological T staging, lymphovascular invasion, perineural and serosal invasion, surgical margin, tumor infiltrated lymphocyte, and tumor budding were examined. The tumor budding of the tumor was made according to the International Tumor Budding Consensus Conference and was classified as low (0-4 buds), intermediate (5-9 buds), high (≥ 10 buds). The relationship between clinical pathologic features, the survival rate, and Axl expression was analyzed with Person’s chi-square, Cox regression tests, and the Kaplan-Meier method. Results: Tumor budding was determined as low in 12, intermediate in 10, and high in 16 cases. The increased degree of tumor budding was associated with focal-diffuse Axl expression (p = 0.018), infiltrative growth patterns (p = 0.031), poor differentiation (p = 0.006), advanced pathological stage (p = 0.002), and serosal (p = 0.040), perineural (p = 0.008), and lymphovascular invasion (p < 0.0001). Overall survival time was shorter in patients with intermediate to high tumor budding compared with those with low tumor budding (p = 0.011). Conclusion: Axl expression appears to be associated with tumor budding capacity, which may be a poor prognostic criterion for patients with gallbladder cancer. It may be a good target to prevent tumor budding to reduce tumor invasion and metastasis.

PDF

___

1. Boutros C, Gary M, Baldwin K, Somasundar P. Gallbladder cancer: Past, present and an uncertain future. Surg Oncol. 2012;21:e183-e191. [CrossRef]
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424. [CrossRef]
3. Wistuba II, Gazdar AF. Gallbladder cancer: Lessons from a rare tumour. Nat Rev Cancer. 2004;4:695-706. [CrossRef]
4. Stratification P, Patients GC. Gallbladder Cancer Patients. Published online 2020.
5. Li M, Lu J, Zhang F, et al. Yes-associated protein 1 (YAP1) promotes human gallbladder tumor growth via activation of the AXL/MAPK pathway. Cancer Lett. 2014;355:201-209. [CrossRef]
6. Ma Z, Dong F, Li Z, et al. A Novel Prognostic Nomogram for Gallbladder Cancer after Surgical Resection: A Single-Center Experience. J Oncol. 2021; 6619149. [CrossRef]
7. Chen C, Geng Z, Shen H, et al. Long-term outcomes and prognostic factors in advanced gallbladder cancer: Focus on the advanced T stage. PLoS One. 2016;11: e0166361. [CrossRef]
8. Du W, Phinney NZ, Huang H, et al. AXL is a key factor for cell plasticity and promotes metastasis in pancreatic cancer. Mol Cancer Res. 2021;19:1412-1421. [CrossRef]
9. Asiedu MK, Beauchamp-Perez FD, Ingle JN, Behrens MD, Radisky DC, Knutson KL. AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells. Oncogene. 2014;33:1316-1324. [CrossRef]
10. Lugli A, Kirsch R, Ajioka Y, et al. Recommendations for reporting tumor budding in colorectal cancer based on the International Budding Consensus Conference (ITBCC) 2016. Mod Pathol. 2017; 1299-1311. [CrossRef]
11. Mitrovic B, Schaeffer DF, Riddell RH, Kirsch R. Tumor budding in colorectal carcinoma: Time to take notice. Mod Pathol. 2012;25:1315-1325. [CrossRef]
12. Liang F, Cao W, Wang Y, Li L, Zhang G, Wang Z. The prognostic value of tumor budding in invasive breast cancer. Pathol Res Pract. 2013;209:269-275. [CrossRef]
13. Gulluoglu M, Yegen G, Ozluk Y, et al. Tumor budding is independently predictive for lymph node involvement in early gastric cancer. Int J Surg Pathol. 2015;23:349-358. [CrossRef]
14. Leoncini E, Ricciardi W, Cadoni G, et al. Adult height and head and neck cancer: A pooled analysis within the INHANCE Consortium. Head Neck. 2014;36:1391. [CrossRef]
15. Lemke G. Biology of the TAM receptors. Cold Spring Harb Perspect Biol. 2013;5: a009076. [CrossRef]
16. Linger RMA, Keating AK, Earp HS, Graham DK. TAM Receptor Tyrosine Kinases: Biologic Functions, Signaling, and Potential Therapeutic Targeting in Human Cancer. Adv Cancer Res. 2008;100:35-83. [CrossRef]
17. Zagórska A, Través PG, Lew ED, Dransfield I, Lemke G. Diversification of TAM receptor tyrosine kinase function. Nat Immunol. 2014;15:920-928. [CrossRef]
18. Colavito SA. AXL as a Target in Breast Cancer Therapy. J Oncol. 2020; 5291952. [CrossRef]
19. Song X, Wang H, Logsdon CD, et al. Overexpression of receptor tyrosine kinase Axl promotes tumor cell invasion and survival in pancreatic ductal adenocarcinoma. Cancer. 2011;117:734-743. [CrossRef]
20. Zhang YX, Knyazev PG, Cheburkin Y V, et al. AXL is a potential target for therapeutic intervention in breast cancer progression. Cancer Res. 2008;68:1905- 1915. [CrossRef]
21. Wium M, Ajayi smith AF, Paccez JD, Zerbini LF. The role of the receptor tyrosine kinase axl in carcinogenesis and development of therapeutic resistance: An overview of molecular mechanisms and future applications. Cancers (Basel). 2021;13:1521. [CrossRef]
22. Zhang Z, Lee JC, Lin L, et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet. 2012;44:852-860. [CrossRef]
23. Vuoriluoto K, Haugen H, Kiviluoto S, et al. Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer. Oncogene. 2011;30:1436-1448. [CrossRef]
24. Li Y, Ye X, Tan C, et al. Axl as a potential therapeutic target in cancer: Role of Axl in tumor growth, metastasis and angiogenesis. Oncogene. 2009;28:3442-3455. [CrossRef]
25. Calvisi DF. When good transforming growth factor-β turns bad in hepatocellular carcinoma: Axl takes the stage. Hepatology. 2015;61:759-761. [CrossRef]
26. Liu CA, Chang CY, Hsueh KW, et al. Migration/invasion of malignant gliomas and implications for therapeutic treatment. Int J Mol Sci. 2018;19:1115. [CrossRef]
27. Tanaka M, Siemann DW. Gas6/Axl signaling pathway in the tumor immune microenvironment. Cancers (Basel). 2020;12:1850. [CrossRef]
28. Xu MZ, Chan SW, Liu AM, et al. AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma. Oncogene. 2011;30:1229-1240. [CrossRef]
29. Koorstra JBM, Karikari CA, Feldmann G, et al. The Axl receptor tyrosine kinase confers an adverse prognostic influence in pancreatic cancer and represents a new therapeutic target. Cancer Biol Ther. 2009;8:618-626. [CrossRef]
30. Leconet W, Larbouret C, Chardès T, et al. Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy. Oncogene. 2014;33:5405-5414. [CrossRef]
31. Wu G, Ma Z, Cheng Y, et al. Targeting Gas6/TAM in cancer cells and tumor microenvironment. Mol Cancer. 2018;17:20. [CrossRef]
32. Hutterer M, Knyazev P, Abate A, et al. Axl and growth arrest-specific gene 6 are frequently overexpressed in human gliomas and predict poor prognosis in patients with glioblastoma multiforme. Clin Cancer Res. 2008;14:130-138. [CrossRef]
33. Shieh YS, Lai CY, Kao YR, et al. Expression of Axl in lung adenocarcinoma and correlation with tumor progression. Neoplasia. 2005;7:1058-1064. [CrossRef]
34. Zhang D, He W, Wu C, et al. Scoring system for tumor-infiltrating lymphocytes and its prognostic value for gastric cancer. Front Immunol. 2019;10:71. [CrossRef]
35. Ramos E, Lluis N, Llado L, et al. Prognostic value and risk stratification of residual disease in patients with incidental gallbladder cancer. World J Surg Oncol. 2020;18:18. [CrossRef]
36. Lin J, Long J, Wan X, et al. Classification of gallbladder cancer by assessment of CD8+ TIL and PD-L1 expression. BMC Cancer. 2018;18:766. [CrossRef]
37. De Smedt L, Palmans S, Andel D, et al. Expression profiling of budding cells in colorectal cancer reveals an EMT-like phenotype and molecular subtype switching. Br J Cancer. 2017;116:58-65. [CrossRef]
38. Hase K, Shatney C, Johnson D, Trollope M, Vierra M. Prognostic value of tumor “budding” in patients with colorectal cancer. Dis Colon Rectum. 1993;36:627-635. [CrossRef]
39. Kai K, Kohya N, Kitahara K, et al. Tumor budding and dedifferentiation in gallbladder carcinoma: potential for the prognostic factors in T2 lesions. Virchows Arch. 2011;449-456. [CrossRef]
40. Kim HN, Lee SY, Kim B hui, Kim CY, Kim A, Kim H. Prognostic value of tumor budding in gallbladder cancer: application of the International Tumor Budding Consensus Conference scoring system. Virchows Arch. 2021;478:1071-1078. [CrossRef]
41. Vivaldi C, Fornaro L, Ugolini C, et al. HER2 Overexpression as a Poor Prognostic Determinant in Resected Biliary Tract Cancer . Oncologist. 2020;25:886-893. [CrossRef]
42. Lamarca A, Barriuso J, McNamara MG, Valle JW. Molecular targeted therapies: Ready for “prime time” in biliary tract cancer. J Hepatol. 2020;73:170-185. [CrossRef]
43. Pais-Costa SR enat, Farah JF de M, Artigiani-Neto R, Martins SJ os, Goldenberg A. Evaluation of P53, E-cadherin, Cox-2, and EGFR protein immunoexpression on prognostic of resected gallbladder carcinoma. Arq Bras Cir Dig. 2014;27:126-132. [CrossRef]